Shenhong Wu

Dr. Shenhong Wu is a Clinical Associate Professor of Medicine specializing in Medical Oncology at Stony Brook University's School of Medicine. He provides clinical care and conducts research focused on cancers of the prostate, bladder, kidney, and testis, with particular expertise in managing dermatologic adverse events associated with cancer treatments. His practice is based at the Stony Brook Cancer Center and The Phillips Family Cancer Center in Southampton.

Dr. Wu's educational background includes:

• Fellowship in IM-Oncology at National Institutes of Health Clinical Center (2006)
• Residency in Internal Medicine at Bridgeport Hospital (Yale University School of Medicine) (2004)
• Post Doctoral Fellowship in Pathology at University of Chicago Division of the Biological Sciences The Pritzker School of Medicine (2001)
• Post Graduate in Surgery at Shanghai Medical University (1990)
• Medical School at Wenzhou Medical College (1987)

Dr. Wu's research focuses on oncology with special emphasis on dermatologic adverse events associated with cancer treatments. His work spans various areas including:

• Management of skin reactions to immunotherapy and targeted cancer therapies
• Comparative effectiveness of treatments for prostate and renal cell carcinoma
• Adverse event profiles of novel anticancer agents
• Meta-analyses of treatment toxicities across multiple cancer types

Analysis of Dr. Wu's recent publications reveals a strong focus on dermatologic complications of cancer therapies. His research consistently examines the incidence, risk factors, and management strategies for skin-related adverse events associated with targeted therapies, immunotherapies, and traditional chemotherapeutic agents. The breadth of his work spans multiple cancer types including prostate, renal, gastric, and others, with particular attention to meta-analyses that provide evidence-based guidance for managing treatment-related toxicities.

Dr. Wu has made significant contributions to understanding the dermatologic side effects of various cancer treatments including:

• PD-1 inhibitors and immune checkpoint inhibitors
• mTOR inhibitors like everolimus
• Multikinase inhibitors such as cabozantinib and sunitinib
• Targeted therapies for prostate and renal cancers

While specific information about his advising activities and grants is not provided in the available text, Dr. Wu's extensive publication record suggests active involvement in research mentorship and likely grant-funded projects related to cancer treatment toxicities and management strategies.

Based on his clinical focus and publications, Dr. Wu appears to be part of multidisciplinary teams specializing in genitourinary oncology and supportive cancer care, with particular expertise in managing dermatologic complications of cancer therapy.